Mission Pharmacal relaunches Lithostat
SAN ANTONIO — Mission Pharmacal announced Friday that it would be relaunching its Lithostat (acetohydroxamic acid) kidney stones treatment. The reintroduction comes as part of a partnership with a French company that supplies the drug’s active ingredients and a distribution arrangement with specialty supplier Transition Patient Services.
“The partnership with TPS enables Mission to provide a patient-friendly service and to make Lithostat available with a consistent and convenient delivery method,” Mission Pharmacal’s executive director of urological and specialty sales Steve Gornto said. “Now everyone knows how and where to get the product and related information. Mission can serve Lithostat patients and do so in an efficient way.”
The company said that the arrangement with TPS would allow its team to reach out to urologists and nephrologists with literature on the drug and provide more information about the kidney stone treatment and how to fulfill orders for Lithostat.
“With the relaunch, Mission is doing everything we can to stand behind the patient and physician to help make sure the people who rely on Lithostat get the therapy they need,” Gornto said.
Report: Business-targeted cyber attacks on the rise
NEW YORK — Symantec has recently reported that three out of five cyber attacks target small and medium-sized businesses, favoring point-of-sale systems at brick and mortar stores.
But 94% of these attacks, which seek merchant and customer information, are preventable, according to Visa. Most cyber attacks involve low to moderate hacking ability, targeting weak passwords or remote access portals that are left open, the company said.
“If a merchant is using a company that is QIR- [qualified integrator reseller] certified, they can be much more confident that their point-of-sale network is properly secured,” Eduardo Perez, head of Global Payments System Security for Visa, said. “More integrator vendors need to get the certification, and more merchants should use them.”
Diplomat to dispense new cholesterol med Repatha
FLINT, Mich. — Diplomat Pharmacy on Friday announced that it would be dispending Amgen’s recently approved cholesterol treatment drug Repatha.
“Statins are the most widely prescribed class of medications for those with high cholesterol, and for those who are statin-intolerant, finding treatment can be difficult," said Gary Kadlec, Diplomat's president. “With Repatha, we are motivated by the thought of offering those patients a new innovative means of treatment.”
Repatha is one in a new class of cholesterol medications called PSCK9 (proprotein convertase substilisin kexin type 9) inhibitors, which are potentially an alternative to statins — albeit an expensive one, as CVS Health highlighted when it called for new guidelines around cholesterol treatment in the Journal of the American Medical Association.